Medical treatment of osteoporosis - Increasing options

被引:0
作者
Leong, KH [1 ]
机构
[1] 04 18 Gleneagles Med Ctr, Singapore 258499, Singapore
关键词
bisphosphonates; calcitonin; fracture risk; hormone replacement therapy; parathyroid hormone; selective oestrogen receptor modulators;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Many drugs are now available for the prevention and treatment of osteoporosis. They have differing levels of evidence of efficacy and each may be used according to clinical indications. Methods: A Medline search of clinical drug trials using various therapeutic agents used for osteoporosis was carried out. Results: Several randomised controlled trials have been carried out using many agents. The agents with the best data to date with regards to the prevention of spine as well as hip fractures in patients with prevalent fractures belong to alendronate and risedronate. Parathyroid hormone has been shown in one trial to reduce the risk of non-vertebral fractures. For reduction of spine fractures, in addition to the above two bisphosphonates, many agents, in particular raloxifene, have been shown to be clearly beneficial. Weaker data exist for hormone replacement, calcitonin, cyclical etidronate and the vitamin D analogues calcitriol and alfacalcidol Conclusion: There are many therapeutic agents shown to be clearly effective in the treatment of osteoporosis.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 56 条
  • [21] CRANNEY A, 2000, COCHRANE DATABASE SY
  • [22] Calcium for prevention of osteoporotic fractures in postmenopausal women
    Cumming, RG
    Nevitt, MC
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (09) : 1321 - 1329
  • [23] Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial
    Cummings, SR
    Black, DM
    Thompson, DE
    Applegate, WB
    Barrett-Connor, E
    Musliner, TA
    Palermo, L
    Prineas, R
    Rubin, SM
    Scott, JC
    Vogt, T
    Wallace, R
    Yates, AJ
    LaCroix, AZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24): : 2077 - 2082
  • [24] RISK-FACTORS FOR HIP FRACTURE IN WHITE WOMEN
    CUMMINGS, SR
    NEVITT, MC
    BROWNER, WS
    STONE, K
    FOX, KM
    ENSRUD, KE
    CAULEY, JC
    BLACK, D
    VOGT, TM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (12) : 767 - 773
  • [25] Effect of calcium and vitamin D supplementation on bone, density in men and women 65 years of age or older
    DawsonHughes, B
    Harris, SS
    Krall, EA
    Dallal, GE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (10) : 670 - 676
  • [26] Management of male osteoporosis: report of the UK Consensus Group
    Eastell, R
    Boyle, IT
    Compston, J
    Cooper, C
    Fogelman, I
    Francis, RM
    Hosking, DJ
    Purdie, DW
    Ralston, S
    Reeve, J
    Reid, DM
    Russell, RGG
    Stevenson, JC
    [J]. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 1998, 91 (02) : 71 - 92
  • [27] Erlacher L, 1997, WIEN KLIN WOCHENSCHR, V109, P270
  • [28] Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene -: Results from a 3-year randomized clinical trial
    Ettinger, B
    Black, DM
    Mitlak, BH
    Knickerbocker, RK
    Nickelsen, T
    Genant, HK
    Christiansen, C
    Delmas, PD
    Zanchetta, JR
    Stakkestad, J
    Glüer, CC
    Krueger, K
    Cohen, FJ
    Eckert, S
    Ensrud, KE
    Avioli, LV
    Lips, P
    Cummings, SR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (07): : 637 - 645
  • [29] NANDROLONE DECANOATE - PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC USE IN OSTEOPOROSIS
    GEUSENS, P
    [J]. CLINICAL RHEUMATOLOGY, 1995, 14 : 32 - 39
  • [30] Fluoride for the treatment of postmenopausal osteoporotic fractures: A meta-analysis
    Haguenauer, D
    Welch, V
    Shea, B
    Tugwell, P
    Adachi, JD
    Wells, G
    [J]. OSTEOPOROSIS INTERNATIONAL, 2000, 11 (09) : 727 - 738